Lannett's shares could reach the USD 52.4 level anytime soon.

The company which engages in pharmaceutical products shows strong fundamentals. Its global sales rose 18% in 2013 and could mount to USD 264 million in 2014, an increase of 74% over the prior year. A similar improvement is expected both in terms of EBITDA and net income. The enterprise value compared to its revenues remains high but positive revisions have been made during the last twelve months. Earnings of about USD 1.52 per share are anticipated for 2014 and USD 2.28 for 2015. All analysts covering this stock hold an overweight overview.

From a technical viewpoint, the security is trading in a bullish trend in the short and the long term. The equity has a great potential of growth and could soon take profit of it. All rising moving averages seem to support prices in the rallying process and suggest there will be no reversal in the short-term. Furthermore, buyers pressure is still dominating exchanges while moving Lannett toward new trading ranges.

According to both technical and fundamental analysis, it seems opportune going long at current prices. The bullish trend should allow the security to aim the USD 52.4 level. However, a stop loss is recommended under the USD 40.5 short term support to avoid a bearish overflow.